Fresenius Medical Care Stock News

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been given a consensus rating of Hold by the twenty ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have given a buy recommendation []

Related Stocks: STM , CRGI , TEP , NESN , GEBN , RI , SGO , KER , KYGA , VIV , DPW , SAN , EVK , FME , YAR , ALO , SU , BARN ,

1Spatial PLC with ticker (LON:SPA) now has a potential upside of 28.6% according to Liberum Capital. [stock_market_widget type="chart" template="basic" color="green" assets="SPA.L" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] Liberum Capital set a target price of 70 GBX for the company, which when compared to the 1Spatial PLC share price of 50 GBX at opening today (09/12/2021) indicates a potential upside of 28.6%. Trading has ranged between 26 (52 week low) and 55 (52 week high) with an average of 72,676 shares exchanging hands daily. The market capitalisation at the time of writing is £53,088,570. 1Spatial plc is a United Kingdom-based holding company. The Company''s principal activity is the development and distribution of software solutions along with associated consultancy and support related to Location Master Data Management (LMDM). The Company''s products include 1Integrate, 1Data Gateway,1Integrate for ArcGIS, 1Edit, 1Generalise, 1Spatial Management Suite, FME, and 1Spatial LMAP.

Fear has returned to Wall Street, with the market falling 4% in a matter of days as the Wall of Worry starts to take its toll.

Fear has returned to Wall Street, with the market falling 4% in a matter of days as the Wall of Worry starts to take its toll.

Cambiar Investors LLC lessened its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,275,753 shares of the companys stock after selling 62,842 shares during the []

Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "U.S. Continuous Renal Replacement Therapy Market Size, Share & Trends Analysis Report by Product (CRRT System, Disposables, Liquids), by Modality (SCUF, CVVH, CVVHD, CVVHDF), and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com''s offering. The U.S. continuous renal replacement therapy market size is expected to reach USD 957.2 million by 2028 and is expected to expand at a CAGR of 6.1%

Fresenius: The Selloff Is Creating A Buying Opportunity

The IT Solution for Dialysis Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The IT Solution for Dialysis

Berenberg Bank set a 78.10 ($88.75) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Wednesday, Borsen Zeitung reports. A number of other analysts also recently issued reports on FME. Credit Suisse Group set a 66.00 ($75.00) price target on Fresenius Medical Care AG & []

Renal Replacement Therapy Market The renal replacement therapy market was valued at USD 923.4 million in 2019 and is expected to grow with a CAGR of 7.4%. Renal replacement therapy was introduced in the late 1970s. Burton introduced the term hemofiltration in 1976 and conducted the

Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a 56.00 ($63.64) price objective by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports. FME has been the topic of several other reports. Barclays set a 73.00 ($82.95) price target on shares []

Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.

Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.